Skip to main content

Table 4 Summary of TEAEs of special interest—incidence by time periods

From: Selinexor plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH): a phase II, single-arm study

Preferred term Study treatment period
1–8 weeks 9–24 weeks >24 weeks
# of subjects continuing treatment, n (%) 82 (100) 58 (100) 23 (100)
 Thrombocytopenia 70 (85.4) 42 (72.4) 18 (78.3)
 Nausea/vomiting 68 (82.9) 21 (36.2) 5 (21.7)
 Fatigue/asthenia 58 (70.7) 15 (25.9) 5 (21.7)
 Neutropenia/febrile neutropenia 54 (65.9) 34 (58.6) 10 (43.5)
 Hyponatremia 52 (63.4) 18 (31.0) 6 (26.1)
 Decreased appetite 46 (56.1) 16 (27.6) 8 (34.8)
 Weight decreased 44 (53.7) 27 (46.6) 7 (30.4)
 Neurotoxicity 24 (29.3) 7 (12.1) 1 (4.3)
 Diarrhea 22 (26.8) 7 (12.1) 1 (4.3)
 Pneumonia 20 (24.4) 7 (12.1) 3 (13.0)
 Vision blurred 5 (6.1) 2 (3.4) 2 (8.7)
 Cataract 1 (1.2) 1 (1.7) 1 (4.3)